John Santini
4 posts
#NEWS: The first patients have been enrolled in our Phase 2 multi-center VISUALIZE study! The study will assess the potential of our tumor-targeted fluorescent imaging agent, VGT-309, to improve visibility of tumors during lung cancer surgery. Read more: vergentbio.com/vergent-bio-in… #clinicaltrials #medtwitter #meded
Today we presented new data at the @IASLC 2023 World Conference on #LungCancer providing compelling evidence that VGT-309 increases the potential that surgeons can identify all tumor tissue during minimally invasive and robotic surgery. #WLCL23 Read more: vergentbio.com/news-2023-sep11
We’ve been awarded a Small Business #Innovation Research grant from @NIH. This will support our study of targeted fluorescent imaging agent to improve #tumorvisualization. Read the announcement: bit.ly/3OHWEzL
Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309. Read the full media release: bit.ly/3M4rLUI #innovation #tumorvisualization
